Globus Medical (GMED) Tops Q2 EPS by 10c; reaffirms guidance

Globus Medical (NYSE: GMED) reported Q2 EPS of $0.86, $0.10 better than the analyst estimate of $0.76. Revenue for the quarter came in at $745.3 million versus the consensus estimate of $739.16 million.

GUIDANCE:

Globus Medical sees FY2025 EPS of $3.00-$3.30, versus the consensus of $3.16. Globus Medical sees FY2025 revenue of $2.8-2.9 billion, versus the consensus of $2.854 billion.

For earnings history and earnings-related data on Globus Medical (GMED) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c